Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of E6201 Plus Dabrafenib for the Treatment of Central Nervous System (CNS) Metastases From BRAF V600-Mutated Metastatic Melanoma

NCT05388877 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05388877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05388877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of E6201 Plus Dabrafenib for the Treatment of Central Nervous System (CNS) Metastases From BRAF V600-Mutated Metastatic Melanoma
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Terminated
Start date
October 20, 2022
Completion date
June 2, 2025
Enrollment
13 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iv cutaneous melanoma ajcc v8, metastatic malignant neoplasm in the brain, metastatic malignant neoplasm in the central nervous system, metastatic melanoma